Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.57 |
| ▸ | RXRA | P19793 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29788601 | 1.00 | MAOB (0.57) | MAOBRXRANPC1RAB9AHTR1A | |
| SCHEMBL24978450 | 0.89 | MAOB (0.73) | MAOBRXRANPC1RAB9APOLB | |
| SCHEMBL6451155 | 0.88 | RXRA (0.57) | MAOBRXRANPC1RAB9AHTR1A | |
| SCHEMBL4939083 | 0.87 | MAOB (0.53) | MAOBRXRANPC1RAB9APOLB | |
| SCHEMBL4941339 | 0.87 | NPC1 (0.53) | MAOBRXRANPC1RAB9AHTR1A | |
| SCHEMBL30800458 | 0.87 | MAOB (0.53) | MAOBRXRANPC1RAB9APOLB | |
| SCHEMBL24978452 | 0.87 | MAOB (0.50) | MAOBRXRANPC1RAB9APOLB | |
| SCHEMBL4520573 | 0.86 | MAOB (0.49) | MAOBNPC1RAB9APOLBSMN1; SMN2 | |
| SCHEMBL12555104 | 0.85 | RXRA (0.46) | MAOBRXRANPC1RAB9AHTR1A | |
| SCHEMBL24978176 | 0.85 | MAOB (0.48) | MAOBNPC1RAB9APOLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12558345-B2 | CHK1/2 inhibitors for use in the treatment of neuroblastomas and/or soft tissue sarcomas | ELI LILLY AND COMPANY (US) | 2026-02-24 | — | — | US | disclosed |
| CN-117715905-A | Checkpoint kinase 1 (CHK 1) inhibitors and uses thereof | 无界生物公司 | 2024-03-15 | — | — | CN | disclosed |
| CN-114728945-B | 3, 5-disubstituted pyrazole compounds as kinase inhibitors and uses thereof | 上海瑛派药业有限公司 | 2024-01-16 | — | — | CN | disclosed |
| US-20230310423-A1 | CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230310423-A1 | CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. | 2023-10-05 | — | — | US | disclosed |
| US-11707462-B2 | Checkpoint kinase 1 (CHK1) inhibitors and uses thereof | BOUNDLESS BIO, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11707462-B2 | Checkpoint kinase 1 (CHK1) inhibitors and uses thereof | BOUNDLESS BIO, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230026313-A1 | CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20220378745-A1 | CHK1/2 INHIBITORS FOR USE IN THE TREATMENT OF NEUROBLASTOMAS AND/OR SOFT TISSUE SARCOMAS | ELI LILLY AND COMPANY | 2022-12-01 | — | — | US | disclosed |
| US-20220378745-A1 | CHK1/2 INHIBITORS FOR USE IN THE TREATMENT OF NEUROBLASTOMAS AND/OR SOFT TISSUE SARCOMAS | ELI LILLY AND COMPANY | 2022-12-01 | — | — | US | disclosed |
| EP-2379532-B1 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | LILLY CO ELI (US) | 2013-02-20 | — | — | EP | disclosed |
| US-8314108-B2 | 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts | ELI LILLY AND COMPANY (US) | 2012-11-20 | — | — | US | disclosed |
| US-8314108-B2 | 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts | ELI LILLY AND COMPANY (US) | 2012-11-20 | — | — | US | disclosed |
| US-8314108-B2 | 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts | ELI LILLY AND COMPANY (US) | 2012-11-20 | — | — | US | disclosed |
| EP-2379532-A1 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | Eli Lilly and Company (US) | 2011-10-26 | — | — | EP | disclosed |
| US-20110144126-A1 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | ELI LILLY AND COMPANY | 2011-06-16 | — | — | US | disclosed |
| US-20110144126-A1 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | ELI LILLY AND COMPANY | 2011-06-16 | — | — | US | disclosed |
| US-20110144126-A1 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | ELI LILLY AND COMPANY | 2011-06-16 | — | — | US | disclosed |
| WO-2010077758-A1 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | ELI LILLY AND COMPANY (US) | 2010-07-08 | — | — | WO | disclosed |
| WO-2010077758-A1 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | ELI LILLY AND COMPANY (US) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310423-A1 | CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF | CHEK1, CHEK2, RAD1 | MAOB 4683/4885RXRA 4400/4885NPC1 3820/4885 |
| US-20110144126-A1 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | CHEK1, CHEK2, PLK1 | MAOB 4835/4885RXRA 4714/4885NPC1 3414/4885 |
| US-11707462-B2 | Checkpoint kinase 1 (CHK1) inhibitors and uses thereof | CHEK1, CHEK2, RAD1 | MAOB 4683/4885RXRA 4400/4885NPC1 3820/4885 |
| US-20220378745-A1 | CHK1/2 INHIBITORS FOR USE IN THE TREATMENT OF NEUROBLASTOMAS AND/OR SOFT TISSUE SARCOMAS | CHEK1, CHEK2, PLK1 | MAOB 4592/4885RXRA 4812/4885NPC1 4786/4885 |
| US-20230026313-A1 | CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF | CHEK1, CHEK2, RAD1 | MAOB 4683/4885RXRA 4400/4885NPC1 3820/4885 |
| US-12558345-B2 | CHK1/2 inhibitors for use in the treatment of neuroblastomas and/or soft tissue sarcomas | CHEK1, CHEK2, MRE11 | MAOB 4712/4885RXRA 4751/4885NPC1 4661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.